Company intelligence / Profile preview

Replicate Bioscience

San Diego, California, United Statesreplicatebioscience.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Replicate Bioscience has demonstrated first-in-human data for its optimized srRNA rabies vaccine in a Phase I study showing safety and immunogenicity. The company reports robust preclinical progress across infectious disease, oncology, and autoimmune indications. Its platform enables high protein expression at low doses with durable effects compared to linear mRNA approaches.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: self-replicating RNA (srRNA)RNA therapeutics/vaccinesImmunotherapiesProtein expression platforms
Industry: Biotech

Drug pipeline

10 assets

RBI-4000

9 more assets in the full pipeline.

Request access →

Partnerships

Exclusive technology license from Duke University for preventing drug-resistant cancer mutations.

Beyond the preview

Go deeper on Replicate Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Replicate Bioscience.

Explore the full profile